143 related articles for article (PubMed ID: 28430623)
1. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q
Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer.
Chen Z; Zhang J; Huang K; Shen Q; Teng X
Int J Clin Exp Pathol; 2018; 11(9):4644-4649. PubMed ID: 31949864
[TBL] [Abstract][Full Text] [Related]
4. The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis.
Wang L; Li Y; Li L; Wu Z; Yang D; Ma H; Wang D
Onco Targets Ther; 2018; 11():2345-2353. PubMed ID: 29731642
[TBL] [Abstract][Full Text] [Related]
5. Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case report.
Cai Z; Huang J; Dai W; Li X; Hong W; Hong Y
Medicine (Baltimore); 2024 Jan; 103(4):e36214. PubMed ID: 38277579
[TBL] [Abstract][Full Text] [Related]
6. A novel ARMS-based assay for the quantification of
Zhu Y; Guo Z; Liu Y; Zheng X; Yang G; Zheng G
Oncol Lett; 2018 Mar; 15(3):2905-2912. PubMed ID: 29435017
[TBL] [Abstract][Full Text] [Related]
7. Case report: Efficacy of icotinib treatment in lung adenocarcinoma with esophageal squamous cell carcinoma: a rare case of double primary malignant tumors.
Deng M; Li X; Mu H; Wei M; Sun L
Front Med (Lausanne); 2024; 11():1266062. PubMed ID: 38606154
[TBL] [Abstract][Full Text] [Related]
8. Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.
Soo RA; Kubo A; Ando M; Kawaguchi T; Ahn MJ; Ou SI
Clin Lung Cancer; 2017 Sep; 18(5):535-542. PubMed ID: 28433570
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
10. Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?
Brighenti M; Petrelli F; Barni S; Conti B; Sarti E; Ratti M; Panni S; Passalacqua R; Bersanelli M
Eur J Cancer; 2017 Jul; 79():149-151. PubMed ID: 28494405
[TBL] [Abstract][Full Text] [Related]
11. Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract][Full Text] [Related]
12. A novel epidermal growth factor receptor inhibitor for treating lung cancer.
Gao J; Liang Y; Zhang D; Wang Y; Yang J; Liu H
Tumour Biol; 2017 Apr; 39(4):1010428317698358. PubMed ID: 28443496
[TBL] [Abstract][Full Text] [Related]
13. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR
J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456
[TBL] [Abstract][Full Text] [Related]
14. A Rare Case of Misdiagnosed Silent Lung Cancer with Solitary Metastasis to the Temporomandibular Joint Condyle.
Guarda-Nardini L; Stellini E; Di Fiore A; Manfredini D
J Oral Facial Pain Headache; 2017 Spring; 31(2):180-185. PubMed ID: 28437516
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001).
Miyawaki M; Naoki K; Yoda S; Nakayama S; Satomi R; Sato T; Ikemura S; Ohgino K; Ishioka K; Arai D; Namkoong H; Otsuka K; Miyazaki M; Tani T; Kuroda A; Nishino M; Yasuda H; Kawada I; Koh H; Nakamura M; Terashima T; Sakamaki F; Sayama K; Betsuyaku T; Soejima K
Mol Clin Oncol; 2017 Mar; 6(3):409-414. PubMed ID: 28451422
[TBL] [Abstract][Full Text] [Related]
16. The effects of supportive care interventions on depressive symptoms among patients with lung cancer: A metaanalysis of randomized controlled studies.
Hsieh CC; Hsiao FH
Palliat Support Care; 2017 Dec; 15(6):710-723. PubMed ID: 28508739
[TBL] [Abstract][Full Text] [Related]
17. Successful lung-sparing resection of synchronous pleural mesothelioma and contralateral lung cancer.
Imanishi N; Nabe Y; Takenaka M; Chikaishi Y; Kuroda K; Noguchi H; Yatera K; Tanaka F
Surg Case Rep; 2017 Dec; 3(1):64. PubMed ID: 28485001
[TBL] [Abstract][Full Text] [Related]
18. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
